COMMUNIQUÉS West-GlobeNewswire

Placement privé de 366 666 $

19/02/2019 - 14:00

MONTRÉAL, 19 févr. 2019 (GLOBE NEWSWIRE) -- CORPORATION TERRANUEVA (la « Société » ou « Terranueva ») est heureuse d’annoncer avoir complété un placement privé d’une somme globale de 366 666 $ en actions ordinaires au [...]

Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

19/02/2019 - 14:00

AK002 has now shown clinical activity in multiple mast cell diseases REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of [...]

Strongbridge Biopharma plc to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call on February 26, 2019

19/02/2019 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]

Amedisys Announces Retirement of Board Member Linda J. Hall

19/02/2019 - 13:30

BATON ROUGE, La., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, announced today that Ms. Linda J. Hall, Ph.D., will retire [...]

Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress

19/02/2019 - 13:30

PHILADELPHIA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today [...]

Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

19/02/2019 - 13:30

DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today [...]

Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference

19/02/2019 - 13:30

SAN DIEGO and TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of [...]

Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder

19/02/2019 - 13:27

Favorable safety and tolerability, linear pharmacokinetics, and ample CNS exposure of NYX-783 observed in Phase 1 Phase 2 data anticipated 1H 2020 EVANSTON, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: [...]

Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society

19/02/2019 - 13:05

- Presentations highlighted data analyses across multiple disease states - - New, nonclinical data indicates potential for suprachoroidal administration of gene-based therapies - ALPHARETTA, Ga., Feb. 19, 2019 (GLOBE [...]

The Joint Corp. Opens First Corporately Managed Greenfield Clinic Since 2016

19/02/2019 - 13:05

- Grew Total Clinics to 442 at December 31, 2018 - - Increased Corporate Clinic Count to 49 as of February 15, 2019 - SCOTTSDALE, Ariz., Feb. 19, 2019 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national [...]

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

19/02/2019 - 13:00

March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, [...]

Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference

19/02/2019 - 13:00

NEW YORK and BASEL, Switzerland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief [...]

William Demant Holding A/S: Notice to annual general meeting

19/02/2019 - 11:45

To the shareholders of William Demant Holding A/S 19 February 2019 Notice is hereby given of the Annual General Meeting of William Demant Holding A/S to be held on: Tuesday, 19 March 2019 at 4:00pm CET at the Company’s [...]

Transactions in relation to share buyback program

19/02/2019 - 10:37

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics

19/02/2019 - 08:30

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient [...]

Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany

19/02/2019 - 08:01

Interim report for Enzymatica AB (publ) JANUARY- DECEMBER 2018 Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany Q4 Net sales reached SEK 18.9 (19.1) million. [...]

Motif Bio Conference Call and Webcast

19/02/2019 - 08:00

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will hold a [...]

Agreement between Bio-on and Innova Imagen for the production of Bioplastic in Mexico

19/02/2019 - 08:00

Bio-on and Innova Imagen (Himes Group) announce the signing of a new agreement to produce ultra-green PHA biopolymers in Mexico The two companies start the first collaboration in the central / north America, to exploit [...]

Saniona Tesomet Phase 2a Prader-Willi syndrome trial update

19/02/2019 - 08:00

PRESS RELEASE February 19, 2019 Tesomet 0.5 mg/day achieved reductions in weight and hyperphagia in adult PWS patients Tesomet 0.125 mg/day was well tolerated in adolescent PWS patients, but did not achieve sufficient [...]